| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 5.88B | 5.78B | 6.03B | 6.79B | 6.34B | 4.97B | 
| Gross Profit | 1.07B | 1.15B | 1.31B | 1.62B | 1.38B | 1.07B | 
| EBITDA | 237.00M | 692.00M | 197.00M | 1.20B | 1.21B | 767.00M | 
| Net Income | -420.00M | 86.00M | -238.00M | 578.00M | 608.00M | 219.00M | 
| Balance Sheet | ||||||
| Total Assets | 7.49B | 7.51B | 8.25B | 7.64B | 7.55B | 7.08B | 
| Cash, Cash Equivalents and Short-Term Investments | 502.00M | 713.00M | 1.20B | 1.10B | 1.45B | 1.10B | 
| Total Debt | 244.00M | 4.36B | 4.30B | 3.81B | 3.93B | 4.28B | 
| Total Liabilities | 7.25B | 6.91B | 7.51B | 6.53B | 6.47B | 6.27B | 
| Stockholders Equity | 237.00M | 604.00M | 737.00M | 1.11B | 1.08B | 813.00M | 
| Cash Flow | ||||||
| Free Cash Flow | -35.00M | -993.00M | 186.00M | 447.00M | 543.00M | 540.00M | 
| Operating Cash Flow | 277.00M | -633.00M | 556.00M | 754.00M | 820.00M | 807.00M | 
| Investing Cash Flow | -310.00M | -353.00M | -229.00M | -284.00M | 220.00M | -234.00M | 
| Financing Cash Flow | -26.00M | -36.00M | 172.00M | -685.00M | -560.00M | -449.00M | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | $2.27B | ― | -0.52% | 1.56% | -3.09% | -106.46% | |
| ― | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
| ― | $1.82B | 97.45 | 1.55% | 2.22% | -5.45% | -87.13% | |
| ― | $1.95B | ― | -106.83% | ― | -14.45% | 49.92% | |
| ― | $2.37B | 46.12 | 2.67% | 3.85% | 4.68% | -62.80% | |
| ― | $2.22B | -2.61 | -34.43% | 3.30% | -11.38% | -690.99% | |
| ― | $1.96B | -4.69 | -87.50% | 4.91% | 2.48% | -459.90% | 
On October 15, 2025, Chemours Company amended its credit agreement to extend the maturity date of a $1.05 billion term loan facility to October 15, 2032, and adjusted the applicable margin rates. This move is likely to impact the company’s financial stability positively by providing more time for repayment and potentially reducing interest expenses. Additionally, on October 13, 2025, Chemours’ subsidiaries entered into a Receivables Purchase Agreement with BNP Paribas Factor GmbH, allowing the sale of receivables up to €180 million. This agreement could enhance liquidity for Chemours by converting receivables into immediate cash, thus supporting its operational cash flow.
The most recent analyst rating on (CC) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.
On September 2, 2025, Chemours Company announced changes in its Board of Directors, appointing Mary Cranston as Chair and Alister Cowan as Lead Independent Director, following Dawn Farrell’s departure to join the Canadian government. These leadership changes are significant for the company’s governance and may influence its strategic direction and stakeholder relations.
The most recent analyst rating on (CC) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.
On August 29, 2025, Dawn Farrell, Chair of the Board of Directors at The Chemours Company, announced her resignation effective September 2, 2025, to take on a new role as Chief Executive Officer of the Major Projects Office under the Canadian government. The company has yet to decide on her successor, signaling a forthcoming announcement regarding the new Chair of the Board.
The most recent analyst rating on (CC) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.
The Chemours Company is a global leader in industrial and specialty chemicals, serving diverse markets such as coatings, plastics, and refrigeration, with a strong presence in thermal and specialized solutions, titanium technologies, and advanced performance materials.
The Chemours Company recently held its earnings call, revealing a strong quarter with positive performance across all segments. The sentiment was largely optimistic, driven by notable successes in the TSS segment with Opteon Refrigerants. However, the company acknowledged operational challenges in the TT and APM segments that could pose risks in the upcoming quarters.
On August 3, 2025, Chemours, Corteva, and DuPont agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all pending environmental claims, including PFAS contamination, related to their operating sites and statewide issues. The settlement involves a $875 million payment over 25 years, with Chemours responsible for 50% of the payments. The agreement also includes mechanisms for future remediation funding and establishes a Reserve Fund for financial security. Additionally, Chemours entered into an agreement to sell its rights to $150 million in insurance proceeds related to PFAS claims to DuPont and Corteva.
The most recent analyst rating on (CC) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.